Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

36
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
36
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

24
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Pneumonia Leads to Sepsis: Clinical Phenotypes and Therapeutic Challenges.

Anaesthesia, critical care & pain medicine·2026
Same author

High-flow nasal cannula oxygen during breaks from noninvasive ventilation after extubation: an observational study.

Intensive care medicine·2026
Same author

Clinical evaluation of the SeptiScore biomarker for the diagnosis of healthcare-associated infections in critically ill trauma patients: a multicenter derivation and validation cohort study.

BMC anesthesiology·2026
Same author

Maternal and perinatal placental dysfunction severity in extremely high values of sFlt1/PlGF ratio: A retrospective observational study.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Immersive Haptic Simulation for Psychomotor Skill Acquisition in Preclinical Prosthetic Dentistry: A Randomized Study.

The International journal of prosthodontics·2026
Same author

Neurological outcomes after out-of-hospital cardiac arrest due to aneurysmal subarachnoid hemorrhage: a multicenter cohort study.

Critical care (London, England)·2026

Related Experiment Video

Updated: May 5, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

28.8K

Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study.

Antoine Roquilly1, Pierre Joachim Mahe, Philippe Seguin

  • 1Department of Anesthesiology and Intensive Care Medicine, University of Nantes, France.

JAMA
|March 24, 2011
PubMed
Summary

Stress-dose hydrocortisone significantly reduced the risk of hospital-acquired pneumonia in intubated trauma patients. This treatment also decreased mechanical ventilation duration and hyponatremia incidence.

More Related Videos

A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
06:50

A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation

Published on: June 10, 2020

2.0K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.6K

Related Experiment Videos

Last Updated: May 5, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

28.8K
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
06:50

A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation

Published on: June 10, 2020

2.0K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.6K

Area of Science:

  • Critical Care Medicine
  • Trauma Management
  • Pharmacology

Background:

  • The role of stress-dose hydrocortisone in severe trauma management remains unclear.
  • Optimal treatment strategies for critically ill trauma patients are essential for improving outcomes.

Purpose of the Study:

  • To evaluate the efficacy of intravenous stress-dose hydrocortisone in reducing hospital-acquired pneumonia in trauma patients.
  • To assess the impact of hydrocortisone on secondary outcomes such as mechanical ventilation duration, hyponatremia, and mortality.

Main Methods:

  • A multicenter, randomized, double-blind, placebo-controlled trial (HYPOLYTE study) involving 150 severe trauma patients.
  • Patients received continuous intravenous hydrocortisone or placebo for 7 days, with treatment adjusted based on adrenal response.
  • Primary outcome was hospital-acquired pneumonia within 28 days; secondary outcomes included ventilation duration, hyponatremia, and death.

Main Results:

  • Hydrocortisone significantly decreased the incidence of hospital-acquired pneumonia by 49% (HR, 0.51; P = .007) in the intention-to-treat analysis.
  • Patients receiving hydrocortisone experienced an increase in mechanical ventilation-free days (4 days, P = .001) and a reduction in hyponatremia (P = .01).
  • No significant difference in mortality was observed between the hydrocortisone and placebo groups (8.2% vs 5.3%, P = .44).

Conclusions:

  • Intravenous stress-dose hydrocortisone is effective in reducing the risk of hospital-acquired pneumonia in intubated trauma patients.
  • Hydrocortisone therapy improves key clinical outcomes, including reduced ventilation duration and hyponatremia.
  • The findings support the use of stress-dose hydrocortisone as an adjunctive therapy in severe trauma management.